Invokana Dosage/Direction for Use





Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
Posology: The recommended starting dose of canagliflozin is 100 mg once daily. In patients tolerating canagliflozin 100 mg once daily who have an eGFR ≥60 mL/min/1.73 m2 or CrCl ≥60 mL/min and need tighter glycaemic control, the dose can be increased to 300 mg once daily orally (see as follows and Precautions).
Care should be taken when increasing the dose in patients ≥75 years of age, patients with known cardiovascular disease, or other patients for whom the initial canagliflozin-induced diuresis poses a risk (see Precautions). In patients with evidence of volume depletion, correcting this condition prior to initiation of canagliflozin is recommended (see Precautions).
When canagliflozin is used as add-on therapy with insulin or an insulin secretagogue (e.g., sulphonylurea), a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycaemia (see Adverse Reactions and Interactions).
Elderly (≥65 Years Old): Renal function and risk of volume depletion should be taken into account (see Precautions).
Patients with Renal Impairment: For patients with an eGFR 60 mL/min/1.73 m2 to <90 mL/min/1.73 m2 or CrCl 60 mL/min to <90 mL/min, no dose adjustment is needed.
Canagliflozin should not be initiated in patients with an eGFR <60 mL/min/1.73 m2 or CrCl <60 mL/min. In patients tolerating canagliflozin whose eGFR falls persistently below 60 mL/min/1.73 m2 or CrCl 60 mL/min, the dose of canagliflozin should be adjusted to or maintained at 100 mg once daily. Canagliflozin should be discontinued when eGFR is persistently below 45 mL/min/1.73 m2 or CrCl persistently below 45 mL/min (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions, Precautions and Adverse Reactions).
Canagliflozin should also not be used in patients with end stage renal disease (ESRD) or in patients on dialysis as it is not expected to be effective in such populations (see Pharmacology: Pharmacokinetics under Actions and Precautions).
Patients with Hepatic Impairment: For patients with mild or moderate hepatic impairment, no dose adjustment is required.
Canagliflozin has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see Pharmacology: Pharmacokinetics under Actions).
Children: The safety and efficacy of canagliflozin in children under 18 years of age have not yet been established. No data are available.
Administration: For oral use.
Invokana should be taken orally once a day, preferably before the first meal of the day. Tablets should be swallowed whole.
If a dose is missed, it should be taken as soon as the patient remembers; however, a double dose should not be taken on the same day.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in